News Center

Home page

Peak Report

News reports

Five highlights of the pharmaceutical industry in 2017

Release time:

2020-08-14

2017 NPC and CPPCC Five Major Points in Pharmaceutical Industry

3# September 3 , 2017 NPC and CPPCC will be held in Beijing. The issues and decisions of the NPC and CPPCC will directly affect the overall trends and trends of the industry in the following year and have a profound impact on the future economy and major assets. The following is a summary of the highlights of 5 in the pharmaceutical industry during the 2017 NPC and CPPCC sessions.

1 , Supply-side Reform: Value Chain Distribution Faces Reconstruction

The so-called supply-side reform is to promote the development of economic industry by liberating productivity from the supply and production sides. As early as last year's Spring Festival, the State Council meeting focused on the pharmaceutical industry and proposed measures such as "aiming at the urgent needs of the masses, improving the safety evaluation and product traceability system, combining the" three medical "linkage reform, and building a pharmaceutical circulation network throughout the township", hoping to promote the innovation and upgrading of the pharmaceutical industry through supply-side reform. From

to this year, the health planning Commission held a press conference on 2 8 , saying that through the implementation of the "action plan to further improve medical services", the service process has been continuously optimized, the medical quality has been continuously improved, the service mode has been continuously innovated, and the doctor-patient relationship has been continuously harmonious. 2017 The Health Planning Commission and the State Administration of Traditional Chinese Medicine have identified 11 key tasks to further improve medical services, including expanding the real-name appointment diagnosis and treatment pilot.

In addition, the General Office of the State Council issued a blockbuster document entitled "Several Opinions on Further Reforming and Improving Drug Production, Circulation and Use Policies" on 2 January 9 , which aroused strong repercussions in the pharmaceutical industry. The "opinion" points out that starting from the three major links of drug production, circulation and use is an important reform document covering the entire pharmaceutical industry chain, which will play a key role in further promoting the supply-side structural reform of the pharmaceutical industry. it will also have a far-reaching impact on the future healthy development of the pharmaceutical industry.

If 2016 is the year of supply-side reform, then 2017 will be the year of deepening the supply-side reform of medical reform. Supply-side structural reform has become the key word of this year's "two sessions" medicine.

2 , medical reform: the formation of a basic medical and health system framework

medical reform has always been a hot issue of concern. the key work points of 2017 published by the health planning Commission proposed that the medical reform should be continuously deepened and the formation of a basic medical and health system framework should be accelerated. These include measures such as promoting the hierarchical diagnosis and treatment system, accelerating the establishment of a modern hospital management system, and implementing the reform of the drug supply guarantee system. In addition, medical reform has also been mentioned in the government work reports of the local two sessions that have been implemented, and various localities have "bright moves" to solve the problem of people seeing a doctor ".

Zhejiang Province has achieved "double sinking and two upgrading" of medical resources through the establishment of a medical consortium, alleviating the current situation of people's difficulty in seeing a doctor, and accelerating the reform of "Internet + medical prices.

medical reform has always been one of the key reform projects promoted by the State Council. Deepening the reform of the medical and health system and strengthening the construction of the medical service system will become the focus of attention and heated discussion among the representatives of the two sessions.

3 , medical and nursing integration: make up for shortcomings and solve the pension problem

With the increasing aging of the population, new requirements have been put forward for the development of medical care. In the "Several Opinions on Accelerating the Development of Elderly Care Services" issued by the State Council in 2013 , it was proposed to "promote the integrated development of medical care and elderly care", which pointed out the direction for the development of my country's elderly care industry. This year, Zhejiang proposed to actively promote the reform of the old-age insurance system, study and formulate a linkage adjustment mechanism for the basic pension for retirees and the minimum standard of basic pension for urban and rural residents, and steadily raise the standards of basic pension and basic pension.

At the National Two Sessions, elderly care has become an issue of high concern, and the quality of life of the elderly in their later years will affect the stability of the entire society. How to improve the quality of elderly care services has received special attention.

, Pollution Control: Hundreds of pharmaceutical companies may face suspension of production

. Environmental protection has always been a topic of close attention throughout the country. According to the data of the legal network voting system, as of 2017

2 April 28 , smog control ranked among the top 10 hot spots of the NPC and CPPCC with 19598 votes. 2017 is the second year of the 13th Five-Year Plan and a key year for environmental protection. Last year in the middle and late of December 1, there was a large-scale continuous severe air pollution in our country. Satellite monitoring shows that the scope of smog was once expanded to 17

provinces, autonomous regions and municipalities in

, covering an area of 142 .09 million square kilometers, that is to say, more than 1/7 of the country was shrouded in smog. With such a "power" of the haze, naturally become the focus of attention of the various provinces. It is no longer news to use ten "haze" volts to describe the weather in Beijing-Tianjin-Hebei region during winter heating. However, after the Spring Festival this year, the "Beijing-Tianjin-Hebei and Surrounding Areas Air Pollution Prevention and Control Work Plan for 2017

(

Draft for Comments ) " ( hereinafter referred to as "Plan" ) once again pushed pharmaceutical companies in the region to the forefront. If this "plan" becomes a reality, hundreds of pharmaceutical enterprises in "2+26 " cities such as Beijing, Tianjin, Shijiazhuang, Jinan, Zhengzhou and Taiyuan will not be allowed to produce for 120 days throughout the year. According to the implementation promotion plan of ( Ten Atmospheric Articles

)

issued by the State Council in 2013 , 2017 is the final assessment year of the action plan. Environmental protection has naturally become one of the hot words of the two sessions this year.

, Reform of State-owned Enterprises: Mixed Reform of Pharmaceutical Enterprises Station in Upport

Since 2016

, various regions have successively issued a number of special supporting documents to implement the "Guiding Opinions on Deepening the Reform of State-owned Enterprises" promulgated and implemented by the CPC Central Committee and the State Council, and the "four beams and eight pillars" of the reform of state-owned enterprises have risen, accelerate from "design" to "construction".

1 Since September, the local two sessions have been intensively held, and the reform of state-owned enterprises has once again become the focus of the local "two sessions. 2016

# Decemberth June 29 , Yunnan Baiyao controlling shareholder Baiyao Holdings introduced about 254 billion yuan to Xinhuadu Industrial Group Co., Ltd. through capital increase. Baiyao Holding's equity structure was changed to Yunnan SASAC and Xinhuadu each holding 50% equity. At present, the company's core business consists of the provincial pharmaceutical company, the pharmaceutical division, the health products division and the traditional Chinese medicine resources division, which are respectively responsible for the four major business sectors of pharmaceuticals, health daily chemical products, traditional Chinese medicine resources products and pharmaceutical commerce. The initial completion of the mixed reform plan of Baiyao Holdings has made Yunnan Baiyao a model of performance growth in the pharmaceutical industry. Since the listing of in 1993 , Yunnan Baiyao has led its peers in performance growth. Compared with listed companies under state-owned enterprises in Yunnan Province, Yunnan Baiyao's return on net assets and other indicators are also far ahead. In the report on accelerating the reform of state-owned enterprises recently released by the Tianjin State-owned Assets Supervision and Administration Commission, the timetable and roadmap for Tianjin Pharmaceutical Group Co., Ltd. to promote the reform of state-owned enterprises clearly emerged. Among them, increasing the intensity of mixed reform, using the listing platform to achieve asset securitization and improving the assessment and incentive mechanism have become the three highlights. Some pharmaceutical industry analysts pointed out that from the perspective of the reform route, Tianyao Group has continued the overall thinking of the current state-owned enterprise reform. It is another typical case of initiating the reform of state-owned enterprises in the pharmaceutical industry after Yunnan Baiyao.

pharmaceutical enterprise reform results show, the company's profitability and overall value has been further improved. On the basis that the top-level design of the reform of state-owned enterprises has been basically completed, the reform of pharmaceutical state-owned enterprises will gradually reach a climax in 2017

, which will affect the future direction of pharmaceutical investment to a certain extent. (article from the network)

More information

Yunnan peak through the safety standard secondary acceptance

On March 21, Yunnan Jianfeng Cement Company successfully passed the evaluation and acceptance of secondary enterprises for safety production standardization. On the same day, a review team composed of leaders of the Yunnan Provincial Work Safety Supervision Bureau and relevant experts reviewed the implementation of the establishment of Yunnan Jianfeng safety production standardization secondary enterprises. According to the 13 elements involved in the "Standard for Assessment and Rating of Safety Production Standardization in Cement Enterprises", the review team conducted strict assessment and scoring item by item through grouping to check the site and review the data, and finally determined that Yunnan Peak passed the standard acceptance of safety standardization secondary enterprises. Yunnan Jianfeng has always attached great importance to safety production. After passing the three-level safety standard enterprise review in 2015, in order to raise the level of enterprise safety management to a new level, in 2016, it began to create secondary safety standardization. Over the past year, Yunnan Jianfeng has insisted on taking the creation of secondary safety standards as the top priority of production and operation management, and has formulated an implementation plan for production safety standardization in accordance with the requirements of national standardization norms. the content covers production safety responsibility system, education and training, safety inspection, safety facilities management and other safety production management standards, systems and post safety operation procedures, while further strengthening daily safety inspection and regularly organizing emergency plan drills, strengthen the investigation and rectification of potential safety hazards and the supervision of important hazard sources, and further consolidate the foundation of enterprise safety production management. After the review, Zhou Jiping, general manager of Yunnan Jianfeng, said that Yunnan Jianfeng will take this standard as a new starting point. On the basis of consolidating the accident-free achievements in production safety for two consecutive years, it will conscientiously implement the main responsibility of production safety and cultivate

2020

07-30

Pharmaceutical Company Invests in Beihui Bio-Peak Pharmaceutical Plate to Expand its Territory

News from our newspaper On February 28, the 10th meeting of the 9th Board of Directors of the Group Company reviewed and approved the "Proposal on Foreign Investment of Subsidiaries" and the "Proposal on Authorizing the Chairman of the Board of Directors." On the same day, Jianfeng Pharmaceutical signed the "Agreement on Capital Increase and Share Transfer of Beijing Huibaoyuan Biotechnology Co., Ltd." and the "Performance Commitment Compensation Agreement" with relevant parties. It is planned to use Beijing Huibaoyuan Biotechnology Co., Ltd. (Beihui Biotechnology) and its holding subsidiary Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd. (Guanghui Pharmaceutical) as a platform to jointly carry out new drug research and development, drug production and operation and other pharmaceutical business cooperation. Beihui Biological formerly known as Beijing Huibaoyuan Biotechnology Co., Ltd. The company has strong capabilities in new drug research and development. The actual controller is James Zhou (Zhou Hua), a returned entrepreneurial Ph.D. from Yale University in the United States, and hired Professor Zheng Yongqi from Yale University in the United States as the director of the Huibaoyuan Science and Technology Committee, focusing on anti-tumor and liver disease research. Through the cooperation with Yale University, we have obtained the patent authorization and commercial development license of the new anti-cancer chemical drug trasatabine (trokacitabine)(which has obtained the national new drug clinical approval in August 2016), the anti-hepatitis B chemical drug Crevudine (Clevudine). Guangxi Huibaoyuan Pharmaceutical Technology Co., Ltd., a subsidiary of Beihui Biology, is located in the third international park "China-Malaysia Qinzhou Industrial Park" jointly built by the Chinese government and foreign governments in Guangxi. It covers an area of 214.46 mu and has production workshops for multiple dosage forms such as percolation, tincture, solid preparations and liquid preparations.

2020

07-31

Peak health marketing and a new "play"

Building a New System, Flattening Management, Spike Health Marketing, New "Fit" On February 17, Spike Health Technology Company held a sales meeting to integrate and adjust the construction of a new marketing system and deploy and implement the 2017 sales work. Chen Daiyou, general manager of Health Technology Company, carefully explained and answered the marketing system construction and sales management assessment methods at the meeting, and reached a consensus on unifying thinking. The sales business of Health Technology Company involves three categories: health care products, plant extracts and Chinese herbal pieces. The product attributes and categories are different, and the product sales channels are diversified. In order to facilitate market expansion and adapt to the rapid response to market changes, the Company focuses on key products, key channels and key markets, adjusts the original division model, combines all sales businesses of the Company, establishes a marketing center, and centralizes and unifies flat management. At the meeting, the Health Technology Company issued the "2017 Sales Management Assessment Measures", which takes sales performance as the leading factor, defines the sales staff's business expenses and market expansion support policies, implements quarterly and annual assessment of sales targets, and directly links the assessment of the progress of sales staff's target tasks with monthly income. After two-way selection, adjustment and implementation of sales positions and target tasks, all sales staff of Health Technology Company have signed a sales economic responsibility system. Chen Daiyou hopes that marketers will build confidence to meet the challenges and grow and progress together with the enterprise. At the same time, he said that the health technology company will focus on strengthening the construction and cultivation of the sales team, and carry out training, learning and experience sharing in various ways, so as to improve the business ability and level of the sales team. (Spike Health)

2020

07-31

Peak health marketing and a new "play"

Building a New System, Flattening Management, Spike Health Marketing, New "Way to Work" On February 17, Spike Health Technology Company held a sales meeting to integrate and adjust the construction of a new marketing system and deploy and implement the 2017 sales work. Chen Daiyou, general manager of Health Technology Company, carefully explained and answered the marketing system construction and sales management assessment methods at the meeting, and reached a consensus on unifying thinking. The sales business of Health Technology Company involves three categories: health care products, plant extracts and Chinese herbal pieces. The product attributes and categories are different, and the product sales channels are diversified. In order to facilitate market expansion and adapt to the rapid response to market changes, the Company focuses on key products, key channels and key markets, adjusts the original business model, unifies all sales businesses of the Company, establishes a marketing center, and centralizes and unifies flat management. At the meeting, the Health Technology Company issued the "2017 Sales Management Assessment Measures", which takes sales performance as the leading factor, defines the sales staff's business expenses and market expansion support policies, implements quarterly and annual assessment of sales targets, and directly links the assessment of the progress of sales staff's target tasks with monthly income. After two-way selection, adjustment and implementation of sales positions and target tasks, all sales staff of Health Technology Company have signed a sales economic responsibility system. Chen Daiyou hopes that marketers will build confidence to meet the challenges and grow and progress together with the enterprise. At the same time, he said that the health technology company will focus on strengthening the construction and cultivation of the sales team, and carry out training, learning and experience sharing in various ways, so as to improve the business ability and level of the sales team. (Spike Health)

2020

07-31

Accident-free factory creation enters "second season"

At the beginning of the new year, a major "highlight" of the company's safety and environmental protection management in recent years-the "second quarter" of the establishment of a safety and environmental protection accident-free factory has also begun. Safety and environmental protection accident-free factory creation activities are an important measure for the company to improve the level of on-site management. The first phase of the activity will start on January 1, 2014 and end at the end of 2016 for a period of three years. Since the launch of the activity, all subordinate enterprises of the company have actively organized publicity and training related to safety and environmental protection, strengthened the awareness of safety and environmental protection of all employees, improved the management and operation level of safety and environmental protection; increased investment in safety and environmental protection facilities and equipment; strengthened safety and environmental protection inspection and self-examination and correction of hidden dangers, and timely organized rectification of hidden dangers; strictly assessed the units and relevant responsible persons of the accident, And the accident situation in the group, in order to arouse vigilance and avoid similar accidents. In the past three years, the company's subsidiaries have achieved remarkable results in standardization, safety, and clean operation. Safety and environmental protection accidents have dropped significantly, and no major accidents have occurred, which has effectively promoted the company's safe and civilized production construction. In the 2016 safety and environmental protection accident-free factory establishment assessment conducted a few days ago, a total of 6 units met the accident-free factory standard, of which Yunnan Jianfeng, Jianfeng International Trade and Pharmaceutical Department met the standard for the second consecutive year, and Daye Jianfeng, Qiubin Factory and Cable Company met the standard in the first year. In order to sum up experience and further improve the level of safety and environmental protection management, the Group decided to continue to open

2020

07-31

What will the Chinese Medicine Act bring us?

At the 25th meeting of the Standing Committee of the 12th National People's Congress in December 2016, the the People's Republic of China Chinese Medicine Law (hereinafter referred to as the Chinese Medicine Law) was deliberated and passed, which will come into effect on July 1 this year. As the first comprehensive law that comprehensively and systematically embodies the characteristics of traditional Chinese medicine, the Law of traditional Chinese Medicine clearly stipulates the service of traditional Chinese medicine, the protection and development of traditional Chinese medicine, the training of talents of traditional Chinese medicine, and the scientific research of traditional Chinese medicine. With the change of people's health concept and the continuous innovation of medical mode in recent years, the role of traditional Chinese medicine in health is becoming more and more important. The promulgation of the "Traditional Chinese Medicine Law" has made the development of Chinese medicine more law-based, and it is bound to bring changes to domestic pharmaceutical companies. So, the peak of the pharmaceutical, health products companies will look at the "Chinese Medicine Law", and will have how to deal with it? A few days ago, the reporter interviewed the pharmaceutical companies and peak health technology companies related to the person in charge. What will the Chinese Medicine Act bring us? Reporter: As the general manager of Peak Pharmaceutical, what do you think of the Chinese Medicine Law? Huang Jinlong (Deputy General Manager of the Group Company and General Manager of the Pharmaceutical Company): the Law of traditional Chinese Medicine defines the important position and development policy of traditional Chinese medicine. The state encourages traditional Chinese medicine and western medicine to learn from each other, complement each other, coordinate development, give full play to their respective advantages, and promote the integration of traditional Chinese and western medicine. Traditional Chinese medicine is a huge knowledge system, reflecting the Chinese nation's understanding of life, health and disease. It is precisely because of the distinctive characteristics of Chinese medicine that the Law of Chinese Medicine is used in Chinese medicine clinics, Chinese medicine physicians and doctors.

2020

07-31

< 1...49 50 51...61 > 跳转到页